Ani Pharmaceuticals (ANIP) Cash from Operations Growth (3y) (2013 - 2026)
Powered by 
Analysis
Ani Pharmaceuticals (ANIP) Cash from Operations Growth (3y) (2013 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 42.84 Bn | 39.19 Bn | 2.15 Bn | 8.25% |
| 2 | Viatris | 19.13 Bn | 18.24 Bn | 1.46 Bn | -10.08% |
| 3 | Dr Reddys Laboratories | 9.91 Bn | 9.74 Bn | 396.53 Mn | -27.48% |
| 4 | Amneal Pharmaceuticals | 5.51 Bn | 5.38 Bn | 334.51 Mn | -23.26% |
| 5 | Bausch Health Companies | 2.30 Bn | 464.50 Mn | 2.10 Bn | 48.16% |
| 6 | Alvotech | 1.50 Bn | 1.36 Bn | 2.56 Mn | - |
| 7 | Ani Pharmaceuticals | 1.49 Bn | 1.13 Bn | 165.89 Mn | 40.06% |
| 8 | Amphastar Pharmaceuticals | 1.00 Bn | 714.13 Mn | 93.47 Mn | -2.23% |
| 9 | Fennec Pharmaceuticals | 402.10 Mn | 360.85 Mn | 17.15 Mn | - |
| 10 | RedHill Biopharma | 178.35 Mn | 178.35 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 40.06% |
| Mar 31, 2026 | 39.67% |
| Dec 31, 2025 | 107.25% |
| Sep 30, 2025 | 129.95% |
| Jun 30, 2025 | 104.89% |
| Mar 31, 2025 | 56.69% |
| Dec 31, 2024 | 48.90% |
| Sep 30, 2024 | 62.73% |
| Jun 30, 2024 | 316.51% |
| Mar 31, 2024 | -4.03% |
| Dec 31, 2023 | 114.26% |
| Sep 30, 2023 | 179.91% |
| Jun 30, 2023 | -0.41% |
| Mar 31, 2023 | 132.26% |
| Dec 31, 2022 | -42.87% |
| Sep 30, 2022 | -45.01% |
| Jun 30, 2022 | -64.12% |
| Mar 31, 2022 | -49.26% |
| Dec 31, 2021 | -34.76% |
| Sep 30, 2021 | -38.37% |